Biological response modifiers in the management of rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  American Journal of Health-System Pharmacy

• Publication date

  2003-02-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/AJHP/60.4.346PMID 12625216
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis.

  2001cited by this paper
• Physiology of cytokine pathways in rheumatoid arthritis.

  2001cited by this paper
• Arterial Inflammation in Mice Lacking the Interleukin 1 Receptor Antagonist Gene

  2000cited by this paper
• A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.

  2000cited by this paper
• Anti-TNF agents in Crohn’s disease

  2000cited by this paper
• Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

  2000cited by this paper
• Development of Chronic Inflammatory Arthropathy Resembling Rheumatoid Arthritis in Interleukin 1 Receptor Antagonist–Deficient Mice

  2000cited by this paper
• Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

  2000cited by this paper
• Review article: safety of infliximab in clinical trials

  1999cited by this paper
• Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

  1999cited by this paper
• Molecular mimicry and autoimmunity.

  1999cited by this paper
• Mucosal IL-7-mediated immune responses in chronic colitis-IL-7 transgenic mouse model

  1999cited by this paper
• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

  1998cited by this paper
• Colonic explant production of IL‐1 and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD)

  1998cited by this paper
• Phase I/II Trial of the Type I Soluble Recombinant Human Interleukin-1 Receptor in HIV-1-Infected Patients

  1998cited by this paper
• Combination therapy with biologic agents in rheumatoid arthritis: perils and promise.

  1998cited by this paper
• Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist.

  1998cited by this paper
• Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

  1998cited by this paper
• Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation

  1998cited by this paper
• Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee.

  1997cited by this paper
• Autoimmune reactivity in inflammatory bowel disease.

  1997cited by this paper
• In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy.

  1997cited by this paper
• Imbalance of the interleukin 1 system in colonic mucosa--association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2.

  1997cited by this paper
• The pathophysiology and treatment of rheumatoid arthritis.

  1997cited by this paper
• Interleukin‐1 and interleukin‐1 receptor antagonist in inflammatory bowel disease.

  1996cited by this paper
• Biologic basis for interleukin-1 in disease.

  1996cited by this paper
• Interleukin-1 beta converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice.

  1996cited by this paper
• Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group.

  1996cited by this paper
• Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra.

  1996cited by this paper
• From basic advances to therapeutic strategies in ulcerative colitis.

  1995cited by this paper
• The type I interleukin‐1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF‐transgenic mice

  1995cited by this paper
• Beneficial effects of tumour necrosis factor‐alpha (TNF‐α) blockade in rheumatoid arthritis (RA)

  1995cited by this paper
• Effects of interleukin-1 and interleukin-1 receptor antagonist in AIDS-Kaposi's sarcoma.

  1995cited by this paper
• Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.

  1995cited by this paper
• Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis.

  1995cited by this paper
• Amelioration of established murine collagen‐induced arthritis with anti‐IL‐1 treatment

  1994cited by this paper
• Cytokines in intestinal inflammation: pathophysiological and clinical considerations.

  1994cited by this paper
• Suppression of juvenile chronic myelogenous leukemia colony growth by interleukin-1 receptor antagonist.

  1994cited by this paper
• Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice.

  1993cited by this paper
• Modulation of cell proliferation and cytokine production in AML by recombinant interleukin-1 receptor antagonist.

  1993cited by this paper
• Interleukin-1 receptor antagonist.

  1993cited by this paper
• Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.

  1993cited by this paper
• Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

  1993cited by this paper
• Effects of tumor necrosis factor alpha (TNF-alpha) on collagen arthritis.

  1992cited by this paper
• Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors.

  1992cited by this paper
• Flare‐up of experimental arthritis in mice with murine recombinant IL‐1

  1992cited by this paper
• Acceleration of onset of collagen‐induced arthritis by intra‐articular injection of tumour necrosis factor or transforming growth factor‐beta

  1992cited by this paper
• Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans.

  1992cited by this paper
• Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors

  1992cited by this paper
• Interleukin-1 enhances the development of type II collagen-induced arthritis only in susceptible and not in resistant mice.

  1992cited by this paper
• Expression of granulocyte‐macrophage colony‐stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor‐α

  1991cited by this paper
• Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

  1991cited by this paper
• Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness.

  1991cited by this paper
• In vivo effects of interleukin-1 on articular cartilage. Prolongation of proteoglycan metabolic disturbances in old mice.

  1991cited by this paper
• Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis.

  1990cited by this paper
• Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression.

  1990cited by this paper
• Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

  1990cited by this paper
• Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.

  1990cited by this paper
• Safety issues related to DMARD therapy.

  1990cited by this paper
• Effects of murine recombinant interleukin 1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation.

  1990cited by this paper
• AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6.

  1990cited by this paper
• An interleukin 1 inhibitor affects both cell-associated interleukin 1-induced T cell proliferation and PGE2/collagenase production by human dermal fibroblasts and synovial cells.

  1990cited by this paper
• Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor

  1990cited by this paper
• Antibody to interleukin 1 inhibits the cartilage degradative and thymocyte proliferative actions of rheumatoid synovial culture medium.

  1990cited by this paper
• Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production.

  1990cited by this paper
• NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control.

  1989cited by this paper
• Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients. Possible involvement in joint destruction.

  1988cited by this paper
• Assessment of radiologic progression in rheumatoid arthritis. A randomized, controlled trial.

  1986cited by this paper

• Therapeutic Potential of Withania somnifera Extract on Experimental Model of Arthritis in Rats: Histological Study

  2022cites this paper
• Recent Advances in Anti-inflammatory Potential of Pyridazinone Derivatives.

  2016cites this paper
• Anti-Inflammatory Activity

  2016cites this paper
• The Study of Pyridazine Compounds on Prostanoids: Inhibitors of COX, cAMP Phosphodiesterase, and TXA2 Synthase

  2014cites this paper
• Safety evaluation and therapeutic efficacy of Habb-e-Asgand, a commonly used antirheumatic polyherbal Unani formulation.

  2013cites this paper
• Evaluation of therapeutic efficacy of Majoon Suranjan, a Unani formulation, in the treatment of rheumatoid arthritis: an experimental study

  2013cites this paper
• Effects of Portabella mushrooms on collagen-induced arthritis, inflammatory cytokines, and body composition in dilute brown non-agouti (DBA1) mice

  2011cites this paper
• Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease.

  2011cites this paper
• Lactobacillus casei reduces the Inflammatory Joint Damage Associated with Collagen-Induced Arthritis (CIA) by Reducing the Pro-Inflammatory Cytokines

  2011cites this paper
• From lab to bedside: emerging clinical applications of thymosin alpha 1.

  2009cites this paper
• From lab to bedside: emerging clinical applications of thymosin α1

  2009cites this paper
• Tocilizumab: the first interleukin-6-receptor inhibitor.

  2008cites this paper
• Potential Use of Plectranthus amboinicus in the Treatment of Rheumatoid Arthritis

  2007influential citation
• Efectividad y seguridad de adalimumab y etanercept en artritis reumatoide en un hospital de tercer nivel

  2006cites this paper
• Alternative decision analysis modeling in the economic evaluation of tumor necrosis factor inhibitors for rheumatoid arthritis.

  2006cites this paper
• Treatment of pain in juvenile idiopathic arthritis: a survey of pediatric rheumatologists.

  2006cites this paper
• Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists.

  2006cites this paper
• [Effectiveness and safety of adalimumab and etanercept for rheumatoid arthritis in a third-level hospital].

  2006cites this paper
• Generation and characterisation of anti-C6 monoclonal antibodies in C6-deficient mice: the search for an anti-C6 therapy.

  2006cites this paper
• Utilisation des inhibiteurs du TNF alpha au cours de la polyarthrite rhumatoïde : enquête nationale sur la pratique des rhumatologues aux États-Unis

  2006cites this paper
• Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors

  2005cites this paper
• Immunology: turning basic research into a therapy.

  2005cites this paper
• [Infliximab in rheumatoid arthritis-use in a third level hospital].

  2005cites this paper
• Infliximab en artritis reumatoide. Utilizacin en un hospital de tercer nivel

  2005cites this paper
• Autologous platelet-rich plasma injected intraarticularly diminished synovial effusion and degree of lameness in horses affected with severe joint disease

  2005cites this paper
• Assessing the cost-effectiveness of tumor necrosis factor inhibitors and prescribing practices of rheumatologists in patients with rheumatoid arthritis

  2005cites this paper
• Tissue repair in rheumatoid arthritis: challenges and opportunities in the face of a systemic inflammatory disease.

  2004cites this paper
• Vitamin D and bone

  2004cites this paper
• Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis.

  2004cites this paper
• Hard labour: bacterial infection of the skeleton.

  2003cites this paper
• First Breath prenatal smoking cessation pilot study: preliminary findings.

  2003cites this paper
• Temporomandibular joint involvement by systemic inflammatory disease with reference to pain modulation and joint tissue destruction

  2003cites this paper
• In vitro anti-inflammatory and pro-aggregative effects of a lipid compound, petrocortyne A, from marine sponges

  2003cites this paper
• A new era in rheumatoid arthritis treatment.

  2003cites this paper
• Anticorps monoclonaux, anticorps thérapeutiques

  2003cites this paper